While chronic LPS treatment regimens, as used by Kitazawa et al. (2005), might be more relevant to AD pathogenesis, tolerance occurs with repeated LPS injections (Pardon, 2015), and this has to be taken into account when trying to identify which inflammatory processes contribute to the tau pathology. This evidence concerns the gene MAPT and Alzheimer disease.